Preview

Атеротромбоз

Расширенный поиск

РАННЕЕ НАЗНАЧЕНИЕ ИНГИБИТОРОВ P2Y12-РЕЦЕПТОРОВ ТРОМБОЦИТОВ БОЛЬНЫМ С ОСТРЫМ КОРОНАРНЫМ СИНДРОМОМ: ПОЛЬЗА ИЛИ ВРЕД?

https://doi.org/10.21518/2307-1109-2018-2-76-86

Полный текст:

Аннотация

Двойная антитромбоцитарная терапия, которая включает аспирин и ингибитор P2Y12-рецепторов тромбоцитов (далее – ингибитор P2Y12), является основным компонентом лечения и вторичной профилактики после ОКС. В последние годы широко дискутируется вопрос о целесообразности раннего назначения ингибиторов P2Y12 больным с ОКС – до проведения коронарной ангиографии, когда коронарная анатомия неизвестна. В обзоре представлена исчерпывающая актуальная информация по этой теме, основанная на данных рандомизированных исследований, регистров, официальных клинических рекомендаций.

Об авторе

Р. М. Шахнович
Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр кардиологии» Министерства здравоохранения Российской Федерации
Россия

Шахнович Роман Михайлович – д.м.н., ведущий научный сотрудник отдела неотложной кардиологии

тел.: +7 (495) 150–44–19

121552, г. Москва, ул. 3-я Черепковская, д. 15а



Список литературы

1. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K. Clopidogrel in Unstable Angina to Prevent Recurrent events trial Investigators. effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345: 494–502.

2. Steinhubl S.R., Berger P.B., Mann J.T. 3rd, Fry E.T., Delago A., Wilmer C., Topol E.J. CReDoInvestigators, Clopidogrel for the Reduction of events During observation. early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002; 288: 2411–2420.

3. Mehta S.R., Yusuf S., Peters R.J., Bertrand M.E., Lewis B.S., Natarajan M.K., Malmberg K., Rupprecht H., Zhao F., Chrolavicius S., Copland I., Fox K.A. Clopidogrel in Unstable angina to prevent Recurrent events trial (CURE) Investigators. effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001; 358: 527–533.

4. Steinhubl S.R., Berger P.B., Brennan D.M., Topol E.J. CREDO Investigators. optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol. 2006; 47: 939–943.

5. Collet J.-Ph., Silvain J., Bellemain-Appaix A., Montalescot G. Pretreatment with P2Y12 Inhibitors in Non–St-Segment–Elevation Acute Coronary Syndrome: An Outdated and Harmful strategy. Circulation. 2014; 130: 1904–1914.

6. Schömig A., Neumann F.J., Kastrati A., Schühlen H., Blasini R., Hadamitzky M., Walter H., Zitzmannroth E.M., Richardt G., Alt E., Schmitt C., Ulm K.A. Randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996; 334: 1084–1089.

7. Giambartolomei A., Diver D.J., Lasorda D.M., Williams D.O., Pocock S.J., Kuntz R.E. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting: stent Anticoagulation Restenosis study Investigators. N Engl J Med. 1998; 339: 1665–1671.

8. Di Sciascio G., Patti G., Pasceri V., Gatto L., Colonna G., Montinaro A. ARMYDA-5 PRELOAD. Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Investigators. J Am Coll Cardiol. 2010 Aug 10; 56(7): 550–557. doi:10.1016/j.jacc.2010.01.067.

9. Zeymer U., Arntz H.-R., Mark B., Fichtlscherer St., Werner G., Schöller R., Zahn R., Diller F., Darius H., Dill Th., Huberclin K. Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. res Cardiol. 2012; 101: 305–312.

10. Almendro-Delia M., Almendro-Delia M., Almendrodelia M., Gonzalez-Torres L., Garcia-Alcantara Á., Reina-Toral A. et al., on behalf of the ARIAM-Andalucía Group. Prognostic Impact of Clopidogrel Pretreatment in Patients With Acute Coronary syndrome Managed Invasively. The American Journal of Cardiology. 2015 April 15; 115(Issue 8): 1019–1026.

11. Koul S., Smith J.G., Scherste´N F., James S., Lagerqvist B., Erlinge D. Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. European Heart Journal. 2011; 32: 2989–2997, doi:10.1093/eurheartj/ehr202.

12. Dörler J., Edlinger M., Hannes F., Alber H.F., Altenberger J., Benzer W. et al. Clopidogrel pretreatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. European Heart Journal. 2011 December 1; 32(Issue 23): 2954–2961.

13. Bellemain-Appaix A., O’Connor S.A., Silvain J. et al. for the ACTION group. Association of Clopidogrel Pretreatment With Mortality, Cardiovascular events, and Major Bleeding Among Patients Undergoing Percutaneous Coronary InterventionA systematic Review and Meta-analysis. JAMA. 2012; 308(23): 2507–2516. doi:10.1001/jama.2012.50788.

14. Rakowski T., Siudak Z., Dziewierz A., Sawina A., Dudek D. Prehospital Clopidogrel Administration in Patients With ST-segment elevation Myocardial Infarction treated With Primary PCI: Real-Life experience From the Multicenter nRDesRegistry. J Invasive Cardiol. 2016 Jun; 28(6): e56-8.

15. Montalescot G., Van ‘T Hof A.W., Lapostolle F. et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J med. 2014 sep 11; 371(11): 1016–1027.

16. Montalescot G., Van ‘T Hof A.W., Bolognese L. et al. effect of Pre-Hospital ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-segment elevation Myocardial Infarction: the ATLANTIC-H2 Analysis. JACC Cardiovasc Interv. 2016 Apr 11; 9(7): 646–656.

17. Bagai A., GoodMan S.G., Cantor W.J., Vicaut E., Bolognese L., Cequier A., Chettibi M., Hammett C.J., Huber K., Janzon M., Lapostolle F., Lassen J.F., Merkely B., Storey R.F., Ten Berg J.M., Zeymer U., Diallo A., Hamm C.W., Tsatsaris A., El Khoury J., Van’t Hof A.W. Duration of ischemia and treatment effects of pre- versus in-hospital ticagrelor in patients with ST-segment elevation myocardial infarction: Insights from the ATLANTIC study. Montalescot G. Am Heart J. 2018 Feb; 196: 56–64. doi: 10.1016/j.ahj.2017.10.021. epub 2017 nov 4.

18. Venetsanos D., Sederholm Lawesson S., Alfredsson J., Janzon M., Cequier A., Chettibi M., Goodman S.G., Van’T Hof A.W., Montalescot G., Swahn E. Association between gender and short-term outcome in patients with stelevation myocardial infraction participating in the international, prospective, randomised Administration of ticagrelor in the catheterisation Laboratory or in the Ambulance for new stelevation myocardial Infarction to open the Coronary artery (ATLANTIC) trial: a prespecified analysis. BMJ Open. 2017 sep 21; 7(9): e015241. doi: 10.1136/bmjopen-2016-015241.

19. Collet J.P., Kerneis M., Lattuca B., Yan Y., Cayla G., Silvain J., Lapostolle F., Ecollan P., Diallo A., Vicaut E., Hamm C.W., Van ‘t Hof A.W., Montalescot G. The effect of prehospital P2Y12 receptor inhibition in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: the ATLANTIC-elderly analysis. Euro Intervention. 2018 Jul 3; pii: EIJ-D-18-00182. doi: 10.4244/EIJ-D-18-00182.

20. Koul S., Smith J.G., Götberg M., Omerovic E., Alfredsson J., Venetsanos D., Persson J., Jensen J., Lagerqvist B., Redfors B., James S., Erlinge D. No Benefit of ticagrelor Pretreatment Compared With treatment During Percutaneous Coronary Intervention in Patients With ST-segmentelevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2018 Mar; 11(3): e005528. doi: 10.1161/CIRCINTERVENTIONS.117.005528.

21. Montalescot G., Bolognese L., Dudek D., Goldstein P., Hamm C., Tanguay J.F., Ten Berg J.M., Miller D.L., Costigan T.M., Goedicke J., Silvain J., Angioli P., Legutko J., Niethammer M., Motovska Z., Jakubowski J.A., Cayla G., Visconti L.O., Vicaut E., Widimsky P. ACCOAST Investigators. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J med. 2013 sep 12; 369(11): 999–1010. doi:10.1056/NEJMoa1308075. epub 2013 sep 1.

22. Bellemain-Appaix A., Kerneis M., O’Connor S.A. et al. Reappraisal of thienopyridine pretreatment in patients with non-stelevation acute coronary syndrome: a systematic review and meta-analysis. BMJ. 2014; 349: g6269.

23. Wiviott S.D., Braunwald E., Mccabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., Neumann F.J., Ardissino D., De Servi S., Murphy S.A., Riesmeyer J., Weerakkody G., Gibson C.M., Antman E.M. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357: 2001–2015.

24. Lemesle G., Laine M., Pankert M., Puymirat E., Cuisset T., Boueri Z., Maillard L., Armero S., Cayla G., Bali L., Motreff P., Peyre J.P., Paganelli F., Kerbaul F., Roch A., Michelet P., Baumstarck K., Bonello L. Early versus delayed invasive strategy for intermediate- and highrisk acute coronary syndromes managed without P2Y12 receptor inhibitor pretreatment: Design and rationale of the eARLY randomized trial. Clin Cardiol. 2018 Jan; 41(1): 5-12. doi: 10.1002/clc.22852. epub 2018 Jan 22.

25. Lattuca B., Belardi D., Demattei C., Schmutz L., Cornillet L., Ledermann B., Macia J.C., Iemmi A., Gervasoni R., Roubille F., Cung T.T., Robert P., Messnerpellenc P., Leclercq F., Cayla G. Safety of Percutaneous Coronary Intervention Without P2Y12 Inhibitor Pretreatment From a Cohort of Unselected Patients. J Invasive Cardiol. 2018 Jul 15; pii: JIC2018715-2.

26. Bhatt D.L., Stone G.W., Mahaffey K.W., Gibson C.M., Steg P.G., Hamm C.W., Price M.J., Leonardi S., Gallup D., Bramucci E., Radke P.W., Widimsky P., Tousek F., Tauth J., Spriggs D., Mclaurin B.T., Angiolillo D.J., Genereux P., Liu T., Prats J., Todd M., Skerjanec S., White H.D., Harrington R.A. CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J med. 2013; 368: 1303–1313.

27. Heestermans A.A., Van Werkum J.W., Taubert D. et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb res. 2008; 122: 776–781.

28. Wallentin L., Varenhorst C., James S. et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirintreated patients with coronary artery disease. Eur Heart J. 2008; 29: 21–30.

29. Gurbel P.A., Bliden K.P., Butler K. et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009; 120: 2577–2585.

30. Alexopoulos D., Xanthopoulou I., Gkizas V., Kassimis G., Theodoropoulos K.C., Makris G., Koutsogiannis n., Damelou A., Tsigkas G., Davlouros P., Hahalis G. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segmentelevation myocardial infarction. Circ Cardiovasc Interv. 2012; 5: 797e804.

31. Valgimigli M., Tebaldi M., Campo G. et al. Prasugrel versus tirofiban bolus with or without short postbolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO trial. JACC Cardiovasc Interv. 2012; 5: 268–277.

32. Parodi G., Valenti R., Bellandi B., Migliorini A., Marcucci R., Comito V., Carrabba N., Santini A., Gensini G.F., Abbate R., Antoniucci D. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol.2013; 61: 1601e1606.

33. Roffi M., Patrono C., Collet J.P. et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the european society of Cardiology (ESC). Eur Heart J. 2016; 37: 267–315.

34. Ibanez В., James S., Agewall S., Antunes M.J., Bucciarelli-Ducci Ch., Bueno H., Caforio A.L.P., Crea F., Goudevenos J.A., Halvorse N S. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the european society of Cardiology (ESC). European Heart Journal. 2018 January 7; 39 (Issue 2): 119–177.


Для цитирования:


Шахнович Р.М. РАННЕЕ НАЗНАЧЕНИЕ ИНГИБИТОРОВ P2Y12-РЕЦЕПТОРОВ ТРОМБОЦИТОВ БОЛЬНЫМ С ОСТРЫМ КОРОНАРНЫМ СИНДРОМОМ: ПОЛЬЗА ИЛИ ВРЕД? Атеротромбоз. 2018;(2):76-86. https://doi.org/10.21518/2307-1109-2018-2-76-86

For citation:


Shakhnovich R.M. EARLY PRESCRIPTION OF PLATELET P2Y12 RECEPTOR INHIBITORS TO PATIENTS WITH ACUTE CORONARY SYNDROME: A BENEFIT OR A HARM? Atherothrombosis. 2018;(2):76-86. (In Russ.) https://doi.org/10.21518/2307-1109-2018-2-76-86

Просмотров: 250


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2307-1109 (Print)
ISSN 2658-5952 (Online)